NanoLogix Inc (NNLX)

[kphone2004]

NanoLogix IncorporatNanoLogix Attends Series of Meetings In Houston



Preparation for Pre-test Development Study


NanoLogix is pleased to announce their attendance at a series of meetings in Houston with Drs. Sebastian and Jonathan Faro and the CEO of a California-based Biotechnology firm. The purpose of the meetings was for coordinating forces for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic. The meetings dealt with organization and staffing of a research study at two major Houston hospitals, funded from both Federal Grants and a raise of investment capital, and the specific personnel required for the successful execution of the study. The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.



The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.



NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.



?Dr. Jonathan Faro, PhD, MD stated: "These are incredibly exciting times for Nanologix. Seeing this study begin to crystallize has been invigorating, and it's wonderful to see other health care providers share an interest in our test, which is the leading diagnostic assay in bacterial identification and determination of antibiotic susceptibility. When speaking with nurses and other doctors, it's extraordinary to see their enthusiasm for the test --- we have found the right home for a study of this magnitude."

NanoLogix Inc.
1- 330-534-0800
Email: [e-mail] // Website: http://www.nanologix.com